Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma

Andrea Anichini, Roberta Mortarini, Cristina Maccalli, Paola Squarcina, Katharina Fleischhauer, Luigi Mascheroni, Giorgio Parmiani

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

To determine whether HLA-A2.1-restricted melanoma Ags exist that are not expressed on normal melanocytes, a panel of 478 T cell clones from six HLA- A2.1+ patients was selected for HLA-A2-restricted lysis of autologous tumor and then tested for differential recognition of HLA-A2.1+ melanomas and normal melanocytes. Four subsets of clones were identified in the panel of 107 HLA-A2-restricted CTL clones. CTL clones from three of the four subsets did not lyse melanocytes, but recognized fresh HLA-A2.1+ melanomas and defined three classes of epitopes, including unique Ags, common melanoma Ags, and Ags shared with neoplastic cells of different histologic origin. These CTL clones did not recognize any of the 10 peptides selected for specific association to HLA-A2.1 and derived from Melan-A/Mart-1, tyrosinase, gp100, or MAGE-3 proteins. By contrast, the fourth subset of HLA-A2.1-restricted CTL clones recognized both melanoma and melanocytes. These CTL clones were directed to a peptide from either Melan-A/Mart-1, tyrosinase, or gp100. By a limiting dilution assay, designed to evaluate the frequency of HLA-A2- restricted CTL precursors (CTLp) directed to melanoma but not to melanocytes, such precursors were found in the peripheral blood or tumor site of five of six HLA-A2.1+ melanoma patients, and their frequency was much higher than the frequency of CTLp recognizing both tumor cells and the melanocytes. These results suggest that in melanoma patients most of the HLA-A2.1-restricted immune repertoire to melanoma is directed to epitopes expressed in the neoplastic but not in the normal cells of the melanocyte lineage.

Original languageEnglish
Pages (from-to)208-217
Number of pages10
JournalJournal of Immunology
Volume156
Issue number1
Publication statusPublished - 1 Jan 1996
Externally publishedYes

Fingerprint

Melanocytes
Neoplasm Antigens
Melanoma
T-Lymphocytes
Clone Cells
HLA-A2 Antigen
MART-1 Antigen
Monophenol Monooxygenase
Epitopes
Neoplasms
Peptides
Cell Lineage

ASJC Scopus subject areas

  • Immunology

Cite this

Anichini, A., Mortarini, R., Maccalli, C., Squarcina, P., Fleischhauer, K., Mascheroni, L., & Parmiani, G. (1996). Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. Journal of Immunology, 156(1), 208-217.

Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. / Anichini, Andrea; Mortarini, Roberta; Maccalli, Cristina; Squarcina, Paola; Fleischhauer, Katharina; Mascheroni, Luigi; Parmiani, Giorgio.

In: Journal of Immunology, Vol. 156, No. 1, 01.01.1996, p. 208-217.

Research output: Contribution to journalArticle

Anichini, A, Mortarini, R, Maccalli, C, Squarcina, P, Fleischhauer, K, Mascheroni, L & Parmiani, G 1996, 'Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma', Journal of Immunology, vol. 156, no. 1, pp. 208-217.
Anichini, Andrea ; Mortarini, Roberta ; Maccalli, Cristina ; Squarcina, Paola ; Fleischhauer, Katharina ; Mascheroni, Luigi ; Parmiani, Giorgio. / Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. In: Journal of Immunology. 1996 ; Vol. 156, No. 1. pp. 208-217.
@article{8ac69b94a7ce420b91cdc2296e620937,
title = "Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma",
abstract = "To determine whether HLA-A2.1-restricted melanoma Ags exist that are not expressed on normal melanocytes, a panel of 478 T cell clones from six HLA- A2.1+ patients was selected for HLA-A2-restricted lysis of autologous tumor and then tested for differential recognition of HLA-A2.1+ melanomas and normal melanocytes. Four subsets of clones were identified in the panel of 107 HLA-A2-restricted CTL clones. CTL clones from three of the four subsets did not lyse melanocytes, but recognized fresh HLA-A2.1+ melanomas and defined three classes of epitopes, including unique Ags, common melanoma Ags, and Ags shared with neoplastic cells of different histologic origin. These CTL clones did not recognize any of the 10 peptides selected for specific association to HLA-A2.1 and derived from Melan-A/Mart-1, tyrosinase, gp100, or MAGE-3 proteins. By contrast, the fourth subset of HLA-A2.1-restricted CTL clones recognized both melanoma and melanocytes. These CTL clones were directed to a peptide from either Melan-A/Mart-1, tyrosinase, or gp100. By a limiting dilution assay, designed to evaluate the frequency of HLA-A2- restricted CTL precursors (CTLp) directed to melanoma but not to melanocytes, such precursors were found in the peripheral blood or tumor site of five of six HLA-A2.1+ melanoma patients, and their frequency was much higher than the frequency of CTLp recognizing both tumor cells and the melanocytes. These results suggest that in melanoma patients most of the HLA-A2.1-restricted immune repertoire to melanoma is directed to epitopes expressed in the neoplastic but not in the normal cells of the melanocyte lineage.",
author = "Andrea Anichini and Roberta Mortarini and Cristina Maccalli and Paola Squarcina and Katharina Fleischhauer and Luigi Mascheroni and Giorgio Parmiani",
year = "1996",
month = "1",
day = "1",
language = "English",
volume = "156",
pages = "208--217",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "1",

}

TY - JOUR

T1 - Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma

AU - Anichini, Andrea

AU - Mortarini, Roberta

AU - Maccalli, Cristina

AU - Squarcina, Paola

AU - Fleischhauer, Katharina

AU - Mascheroni, Luigi

AU - Parmiani, Giorgio

PY - 1996/1/1

Y1 - 1996/1/1

N2 - To determine whether HLA-A2.1-restricted melanoma Ags exist that are not expressed on normal melanocytes, a panel of 478 T cell clones from six HLA- A2.1+ patients was selected for HLA-A2-restricted lysis of autologous tumor and then tested for differential recognition of HLA-A2.1+ melanomas and normal melanocytes. Four subsets of clones were identified in the panel of 107 HLA-A2-restricted CTL clones. CTL clones from three of the four subsets did not lyse melanocytes, but recognized fresh HLA-A2.1+ melanomas and defined three classes of epitopes, including unique Ags, common melanoma Ags, and Ags shared with neoplastic cells of different histologic origin. These CTL clones did not recognize any of the 10 peptides selected for specific association to HLA-A2.1 and derived from Melan-A/Mart-1, tyrosinase, gp100, or MAGE-3 proteins. By contrast, the fourth subset of HLA-A2.1-restricted CTL clones recognized both melanoma and melanocytes. These CTL clones were directed to a peptide from either Melan-A/Mart-1, tyrosinase, or gp100. By a limiting dilution assay, designed to evaluate the frequency of HLA-A2- restricted CTL precursors (CTLp) directed to melanoma but not to melanocytes, such precursors were found in the peripheral blood or tumor site of five of six HLA-A2.1+ melanoma patients, and their frequency was much higher than the frequency of CTLp recognizing both tumor cells and the melanocytes. These results suggest that in melanoma patients most of the HLA-A2.1-restricted immune repertoire to melanoma is directed to epitopes expressed in the neoplastic but not in the normal cells of the melanocyte lineage.

AB - To determine whether HLA-A2.1-restricted melanoma Ags exist that are not expressed on normal melanocytes, a panel of 478 T cell clones from six HLA- A2.1+ patients was selected for HLA-A2-restricted lysis of autologous tumor and then tested for differential recognition of HLA-A2.1+ melanomas and normal melanocytes. Four subsets of clones were identified in the panel of 107 HLA-A2-restricted CTL clones. CTL clones from three of the four subsets did not lyse melanocytes, but recognized fresh HLA-A2.1+ melanomas and defined three classes of epitopes, including unique Ags, common melanoma Ags, and Ags shared with neoplastic cells of different histologic origin. These CTL clones did not recognize any of the 10 peptides selected for specific association to HLA-A2.1 and derived from Melan-A/Mart-1, tyrosinase, gp100, or MAGE-3 proteins. By contrast, the fourth subset of HLA-A2.1-restricted CTL clones recognized both melanoma and melanocytes. These CTL clones were directed to a peptide from either Melan-A/Mart-1, tyrosinase, or gp100. By a limiting dilution assay, designed to evaluate the frequency of HLA-A2- restricted CTL precursors (CTLp) directed to melanoma but not to melanocytes, such precursors were found in the peripheral blood or tumor site of five of six HLA-A2.1+ melanoma patients, and their frequency was much higher than the frequency of CTLp recognizing both tumor cells and the melanocytes. These results suggest that in melanoma patients most of the HLA-A2.1-restricted immune repertoire to melanoma is directed to epitopes expressed in the neoplastic but not in the normal cells of the melanocyte lineage.

UR - http://www.scopus.com/inward/record.url?scp=0030029651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030029651&partnerID=8YFLogxK

M3 - Article

VL - 156

SP - 208

EP - 217

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 1

ER -